Featured (left - right), Dr. Mariano Garcia-Blanco, Dr. Rene Jaeggi and Dr. Subhash Vasudevan, beside SABio's first siRNA synthesiser (MerMade 192) from BioAutomation.
| 13 April 2011, Singapore. Specialized biologics will soon be made right here in Singapore to service the booming biomedical science industry regionally. Newly launched biotech company Singapore Advanced Biologics (SABio) will focus on the design, synthesis and validation of specialised biologics or medicinal products, with an initial focus on siRNA, DNA and antibodies. |
Because good quality biologics are more expensive and take longer to arrive in Singapore laboratories relative to those in the US, Japan and Europe, scientists in Singapore face a competitive disadvantage. However, SABio will help alleviate this disadvantage by providing the local and fast-expanding Asian research community with high-quality, affordable and on-time research reagents.
‘SABio’s high quality products will enjoy the valued status of the ‘Made in Singapore’ brand and thus support the vision of Singapore as a research and biomedicine hub,’ said Rene Jaeggi, SABio’s managing director.
SABio was founded by two entrepreneurial researchers at the Duke-NUS Graduate Medical School, Mariano Garcia-Blanco and Subhash Vasudevan.
It also recently closed its Series A financing with an investment from BV Healthcare II, a life science fund managed by BioVeda Capital.
‘SABio’s high quality products will enjoy the valued status of the ‘Made in Singapore’ brand and thus support the vision of Singapore as a research and biomedicine hub,’ said Rene Jaeggi, SABio’s managing director.
SABio was founded by two entrepreneurial researchers at the Duke-NUS Graduate Medical School, Mariano Garcia-Blanco and Subhash Vasudevan.
It also recently closed its Series A financing with an investment from BV Healthcare II, a life science fund managed by BioVeda Capital.
RSS Feed
